News - Afinitor

Filter

Current filters:

Afinitor

Popular Filters

Novartis breast cancer drug Afinitor not cost effective for NHS, says draft NICE guidance

08-07-2013

Swiss drug major Novartis' (NOVN: VX) breast cancer drug Afinitor (everolimus) is not recommended as…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

03-05-2013

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast…

AfinitoreverolimusHerceptinNovartisOncologyPharmaceuticalResearchRochetrastuzumab

NICE issues negative draft decision for Novartis' Afinitor

21-03-2013

The UK's National Institute for Health and Clinical Excellence (NICE) today (March 21) issued an Appraisal…

AfinitorEuropeNovartisOncologyPharmaceuticalPricingRegulation

Growing patient population to drive Mexican breast cancer market

20-02-2013

An expanding patient population will largely contribute to the growth of the market for treating breast…

AfinitorEisaiHalavenKadcylaMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheSouth Americatrastuzumab emtansine

US oncologists' perceptions of Roche's Perjeta very promising

07-09-2012

Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

New entrants from Roche and Novartis will drive breast cancer market

20-08-2012

Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

Added European indications for Abbott's Humira and Novartis' Afinitor

30-07-2012

US health care major Abbott Laboratories (NYSE: ABT) today announced that the European Commission (EC)…

Abbott LaboratoriesAfinitorAnti-Arthritics/RheumaticsEuropeHumiraNovartisOncologyPharmaceuticalRegulation

FDA backs Novartis' Afinitor for advanced breast cancer

23-07-2012

There was good news for Swiss drug major Novartis (NOVN: VX) on Friday, when the US Food and Drug Administration…

AfinitorNorth AmericaNovartisOncologyPharmaceuticalRegulation

US FDA backs new indications for Votrient and Afinitor

29-04-2012

The US Food and Drug Administration last week gave its approval for new indications for currently marketed…

AfinitorGlaxoSmithKlineNorth AmericaNovartisOncologyPharmaceuticalRegulationVotrient

Breast cancer therapy news at SABCS

09-12-2011

This year’s CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in Texas, USA, heard of developments…

AfinitorGenerex BiotechnologyNovartisOncologypertuzumabPharmaceuticalResearchRoche

EU approval for Janssen-Cilag’s Zytiga in prostate cancer and Novartis’ Votubia for SEGA

08-09-2011

Belgium-based Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson (NYSE:…

AfinitorEuropeJanssen-CilagJohnson & JohnsonNovartisOncologyPharmaceuticalRegulationVotubiaZytiga

Novartis’ Afinitor approved in EU for advanced pancreatic neuroendocrine tumors

06-09-2011

The European Commission has approved Swiss drug major Novartis’ (NOVN: VX) Afinitor (everolimus)…

AfinitorEuropeNovartisOncologyPharmaceuticalRegulation

Back to top